Zobrazeno 1 - 10
of 800
pro vyhledávání: '"D L Bhatt"'
Autor:
E. Federti, A. Matte’, M. Hamza, A. Lafferty, D. Coughlan, M. Weissbach, D. L. Bhatt, V. Riccardi, R. Perissinotto, A. Siciliano, J. Climax, C. Brugnara, L. De Franceschi
Publikováno v:
HemaSphere, Vol 6, Pp 1365-1366 (2022)
Externí odkaz:
https://doaj.org/article/eb2a7b04aa7d4fd4b4f1a62bb1e14c9d
Autor:
J.-P. Collet, H. Thiele, E. Barbato, O. Barthélémy, J. Bauersachs, D. L. Bhatt, P. Dendale, M. Dorobantu, T. Edvardsen, T. Folliguet, Ch. P. Gale, M. Gilard, A. Jobs, P. Jüni, E. Lambrinou, B. S. Lewis, Ju. Mehilli, E. Meliga, B. Merkely, O. Mueller, M. Roffi, F. H. Rutten, D. Sibbing, G. C.M. Siontis
Publikováno v:
Российский кардиологический журнал, Vol 26, Iss 3 (2021)
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Externí odkaz:
https://doaj.org/article/873ad287bb7d4778ae7d3f443a713a87
Publikováno v:
European Journal of Preventive Cardiology. 30
Funding Acknowledgements Type of funding sources: Private company. Main funding source(s): Amarin Pharmaceutical, Inc. Elucida Research LLC. Background Omega-3 fatty acid (n3-FA) treatment reduces cardiovascular (CV) risk in relation to circulating E
Publikováno v:
European Journal of Preventive Cardiology. 30
Funding Acknowledgements Type of funding sources: Private company. Main funding source(s): Amarin Pharmaceutical, Inc. Elucida Research LLC. Background Neutrophil degranulation contributes to atherogenesis and tissue injury in response to cytokine re
Publikováno v:
European Heart Journal. 43
Background Aldosterone is an important mediator of hypertension, particularly resistant hypertension, heart failure, and chronic kidney disease. PB6440 is a potent inhibitor of aldosterone synthase (CYP11B2) with high selectivity over the closely rel
Autor:
S Goodman, P G Steg, M Szarek, D L Bhatt, V A Bittner, R Diaz, R A Harrington, J W Jukema, H D White, A M Zeiher, G Manvelian, Y Poulouin, M Scemama, W Stipek, G G Schwartz
Publikováno v:
European Heart Journal. 43
Background In the ODYSSEY OUTCOMES trial (NCT01663402), alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), lowered low-density lipoprotein cholesterol from ∼2.3 mmol/L to ∼1.0 mmol/L at 4 months, reduced t
Autor:
M Pareek, K H Kragholm, M Vaduganathan, J L Pallisgaard, C Byrne, A M D Kristensen, T Biering-Sorensen, C J Lee, A N Bonde, M Maeng, E L Fosbol, L Kober, G H Gislason, D L Bhatt, C Torp-Pedersen
Publikováno v:
European Heart Journal. 43
Background High-sensitivity troponin assays allow for accurate and rapid rule-in or rule-out of myocardial infarction (MI) among patients with acute-onset chest pain. However, prognostic implications of serial high-sensitivity troponin concentrations
Autor:
P Steg, M Szarek, M Valgimigli, S Islam, A M Zeiher, D L Bhatt, V A Bittner, R Diaz, S G Goodman, R A Harrington, J W Jukema, R Pordy, M Scemama, H D White, G G Schwartz
Publikováno v:
European Heart Journal. 43
Background Many patients require arterial revascularization after an index ACS. Lipoprotein(a) is thought to play a pathogenic role in atherothrombosis. In the ODYSSEY OUTCOMES trial, the PCSK9 inhibitor alirocumab reduced major adverse cardiovascula
Autor:
M Pareek, D L Bhatt, L Zheng, J J Lee, L A Leiter, T Simon, S R Mehta, R A Harrington, K Fox, A Himmelmann, E Vidal-Petiot, P G Steg
Publikováno v:
European Heart Journal. 43
Background Various BP characteristics, e.g., systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP), as well as heart rate (HR) may affect the risk of both cardiovascular events and bleeding events. However, the exact
Autor:
M Pareek, C Byrne, A D Mikkelsen, A M Dyrvig Kristensen, M Vaduganathan, T Biering-Sorensen, K H Kragholm, M B Mortensen, A Singh, M H Olsen, D L Bhatt
Publikováno v:
Pareek, M, Byrne, C, Mikkelsen, A D, Kristensen, A M D, Vaduganathan, M, Biering-Sorensen, T, Kragholm, K H, Mortensen, M B, Singh, A, Olsen, M H & Bhatt, D L 2021, ' Marital status, cardiovascular events, and intensive blood pressure lowering among men and women in the Systolic Blood Pressure Intervention Trial ', European Heart Journal, vol. 42, no. Suppl. 1, pp. 2312 . https://doi.org/10.1093/eurheartj/ehab724.2312
Background Married persons may have lower rates of mortality and cardiovascular disease (CV) than unmarried persons although data regarding potential differences between men and women are conflicting. The Systolic Blood Pressure Intervention Trial (S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6db227fc2e4f53e2018d9ee1d28b9d5d
https://vbn.aau.dk/da/publications/742878af-2116-48d8-833a-77114e7bd9e9
https://vbn.aau.dk/da/publications/742878af-2116-48d8-833a-77114e7bd9e9